- Trial phase
- Preclinical / IND-enabling
- Time to market
- Not stated
- Why 2/10
- IM-1335 is a preclinical ADC candidate that was nominated in late 2024 with IND-enabling work initiated. No IND filing, clinical trial start, or any hard dated catalyst has been publicly identified. There is no scheduled binary event for this drug in the next ~12 months.
IM-1335 is a very early-stage preclinical ADC candidate at Immunome, nominated alongside IM-1617 and IM-1340 in late 2024. The company has since advanced IM-1617 and IM-1340 into IND clearance and Phase 1, but no IND filing or clinical update for IM-1335 has been announced. Watch for any mention in future quarterly updates or corporate presentations. The drug is not a meaningful driver of IMNM's valuation at this stage; the stock's thesis rests on varegacestat (PDUFA April 28, 2027) and the IM-1021 ADC program.
Price Chart
Executive Summary
IM-1335 is a preclinical antibody-drug conjugate (ADC) candidate from Immunome Inc. (Nasdaq: IMNM), a clinical-stage oncology company. It was nominated as a development candidate in late 2024 alongside IM-1617 and IM-1340, with IND-enabling work initiated at that time. However, as of Immunome's most recent Q3 2026 financial and business update (November 9, 2026), no IND filing, clinical trial, or specific update on IM-1335 has been publicly disclosed. The company has instead advanced IM-1617 (IND cleared April 2026, Phase 1 dosed June 2026), IM-1340 (IND cleared September 2026), and IM-1021 (Phase 1 data reported November 2026). IM-1335's specific target antigen has not been disclosed. Immunome's primary value driver is varegacestat for desmoid tumors (PDUFA April 28, 2027), and IM-1335 is a minor, early-stage pipeline asset with no near-term catalyst.
How It Works
IM-1335 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy that links a cancer-cell-seeking antibody to a chemotherapy payload. The antibody homes in on a protein found on cancer cells, and when it binds, the cell absorbs the drug and the chemotherapy is released inside the cancer cell, killing it while largely sparing healthy tissue. The specific target of IM-1335 has not been publicly disclosed.
Trial Status
IM-1335 was nominated as a novel ADC candidate in late 2024 with IND-enabling studies initiated. As of the most recent Q3 2026 business update, no IND filing or clinical trial initiation for IM-1335 has been announced, while other pipeline candidates (IM-1617, IM-1340, IM-1021) have advanced into Phase 1.
The Two-Sided Case
Upcoming Catalysts
- No specific catalyst identified for IM-1335. The broader Immunome pipeline has varegacestat PDUFA on April 28, 2027, and IM-1021 data at ASH December 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Immunome Inc. S-3ASR IMNM ·Originating report